Biopharma major Biocon and its partner U.S.-based Quark Pharmaceuticals said on Thursday they had received approval from the Drug Controller General of India (DCGI), to proceed with the study of a siRNA therapy in India. According to a statement, this is the first ever siRNA clinical trial approved by DCGI to develop a new drug that is aimed at treating nerve damage in the eyes.
“The QRK207 study will determine the effect of QPI-1007 on visual function in subjects with acute non-arteritic ischemic optic neuropathy, which is a rare ocular disorder with an unmet need globally,” it said.
